Axsome Therapeutics (AXSM) Short term Debt (2016 - 2026)

Axsome Therapeutics has disclosed Short term Debt across 10 years of filings, most recently posting $11.2 million for Q1 2026.

• Short term Debt for Q1 2026 came in at $11.2 million, up 29.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.2 million (up 29.62% YoY), and the FY2025 annual result was $10.0 million, changed N/A from the prior year.
• Short term Debt came in at $11.2 million for Q1 2026 at Axsome Therapeutics, up from $10.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $70.0 million in Q2 2025 to a low of $5.9 million in Q4 2022.
• The 5-year median for Short term Debt is $7.0 million (2022), against an average of $11.7 million.
• Across the five-year window, Short term Debt declined 4.69% in 2023 and jumped 894.32% in 2025, its largest moves.
• Axsome Therapeutics' Short term Debt stood at $5.9 million in 2022, then increased by 8.59% to $6.4 million in 2023, then grew by 26.91% to $8.1 million in 2024, then climbed by 23.13% to $10.0 million in 2025, then climbed by 11.37% to $11.2 million in 2026.
• The last three Short term Debt figures came in at $11.2 million (Q1 2026), $10.0 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.